SCHEMBL17008307

SCHEMBL17008307

O=C(O)C1CCCCC1c1n[nH]cc1Br

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK2 P25098 2/20 0.33
CASP6 P55212 1/20 0.33
CASP8 Q14790 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HSD17B10 Q99714 3/20 0.33
TSHR P16473 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
HSPA1A P0DMV8 1/20 0.32
HSPA8 P11142 1/20 0.32
GNG2 P59768 1/20 0.32
GNB1 P62873 1/20 0.32
PHLPP2 Q6ZVD8 1/20 0.32
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17008339 0.84 SLC6A2 (0.45)
SCHEMBL17020281 0.84 SLC6A2 (0.45)
SCHEMBL17008637 0.78 POLB (0.36) TSHR
SCHEMBL17008772 0.66 SLC6A4 (0.31) HSD17B10TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL21001854 0.64 MAPK8 (0.30)
SCHEMBL3469250 0.64 MAPK8 (0.30)
SCHEMBL12354198 0.63 KCNQ3 (0.56) L3MBTL1HPGDCYP2C19TAAR1FABP5
SCHEMBL22492062 0.63 KCNQ3 (0.56) L3MBTL1HPGDCYP2C19TAAR1FABP5
SCHEMBL22492058 0.63 KCNQ3 (0.56) L3MBTL1HPGDCYP2C19TAAR1FABP5
SCHEMBL838634 0.63 KCNQ3 (0.56) L3MBTL1HPGDCYP2C19TAAR1FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3104705-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-03 EP disclosed
US-9656990-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-05-23 US disclosed
EP-3104705-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-12-21 EP disclosed
US-20160355502-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-08 US disclosed
WO-2015123089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-08-20 WO disclosed
WO-2015120580-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355502-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ GRK2 3133/4885CASP6 613/4885CASP8 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.